Literature DB >> 9863958

Determination of fluoxetine and norfluoxetine in human plasma by high-pressure liquid chromatography with fluorescence detection.

M A Raggi1, R Mandrioli, G Casamenti, F Bugamelli, V Volterra.   

Abstract

Fluoxetine is an atypical antidepressant drug, which selectively inhibits the neuronal reuptake of serotonin, and is widely used in the treatment of depressive disorders. The aim of this research is the development of an HPLC method with fluorescence detection for the monitoring of fluoxetine plasma levels. The determination requires no more than 250 microl of plasma, which undergo solid phase extraction (SPE), then are injected in the HPLC. For the analytical separation a reversed phase C8 column (150 x 4.6 mm I.D.) was used, while the mobile phase was a mixture of acetonitrile and water containing perchloric acid and tetramethylammonium perchlorate (flow rate: 1 ml min(-1)). The very low levels of analytes in plasma required the employment of a fluorescence detector (lambda(exc) = 230 nm, lambda(em)=290 nm), which also granted a good selectivity. Fluoxetine is revealed as a single peak at a retention time of 9.7 min, while norfluoxetine, the main metabolite of fluoxetine, is revealed at a retention time of 8.1 min. Linearity was obtained over the concentration range 8-200 ng ml(-1) for both substances. The method seems suitable, in accuracy and precision, for the determination of fluoxetine plasma levels of patients; furthermore, it is rapid and sensitive.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9863958     DOI: 10.1016/s0731-7085(98)00170-8

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  2 in total

1.  Antidepressant drugs act by directly binding to TRKB neurotrophin receptors.

Authors:  Plinio C Casarotto; Mykhailo Girych; Senem M Fred; Vera Kovaleva; Rafael Moliner; Giray Enkavi; Caroline Biojone; Cecilia Cannarozzo; Madhusmita Pryiadrashini Sahu; Katja Kaurinkoski; Cecilia A Brunello; Anna Steinzeig; Frederike Winkel; Sudarshan Patil; Stefan Vestring; Tsvetan Serchov; Cassiano R A F Diniz; Liina Laukkanen; Iseline Cardon; Hanna Antila; Tomasz Rog; Timo Petteri Piepponen; Clive R Bramham; Claus Normann; Sari E Lauri; Mart Saarma; Ilpo Vattulainen; Eero Castrén
Journal:  Cell       Date:  2021-02-18       Impact factor: 41.582

2.  Stability-indicating Simultaneous HPTLC Method for Olanzapine and Fluoxetine in Combined Tablet Dosage Form.

Authors:  C R Shah; B N Suhagia; N J Shah; D R Patel; N M Patel
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.